LYEL
Lyell Immunopharma, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.49
P/S
14042.53
EV/EBITDA
-2.53
DCF Value
$0.88
FCF Yield
-35.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-6558.3%
Operating Margin
-566038.9%
Net Margin
-762355.6%
ROE
-90.5%
ROA
-80.7%
ROIC
-70.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $6.0K | $-140.7M | $-6.62 |
| FY 2025 | $36.0K | $-274.4M | $-16.06 |
| Q3 2025 | $15.0K | $-38.8M | $-2.13 |
| Q2 2025 | $8.0K | $-42.7M | $-2.89 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.07
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.